سعر ارديولازين 25مجم 30 قرص 2022

Ardiolazin 25 mg film-coated tablets (hydralazine 25 mg), a direct-acting vasodilator antihypertensive made by Pharma Cure Pharmaceuticals, Egypt; pack of 30 tablets (3 strips).

• Essential hypertension, alone or as an adjunctPopulation: Adults (US label)DailyMed (U.S. National Library of Medicine)
• Moderate to severe hypertension as an adjunct to other antihypertensive agentsPopulation: Adultselectronic medicines compendium (eMC)
• Moderate to severe chronic congestive heart failure, with long-acting nitrates, when optimal diuretics and cardiac glycosides are insufficient and ACE inhibitors are unsuitablePopulation: Adultselectronic medicines compendium (eMC)

• Common: headache, anorexia, nausea, vomiting, diarrhoea, palpitations, tachycardia and angina pectoris. Less frequent: constipation, paralytic ileus, hypotension, paradoxical pressor response, oedema, dyspnoea, peripheral neuritis, dizziness, tremors, muscle cramps, psychotic reactions, difficulty in urination, blood dyscrasias, lymphadenopathy, splenomegaly, hypersensitivity reactions (rash, urticaria, pruritus, fever, chills, arthralgia, eosinophilia, rarely hepatitis), nasal congestion, flushing, lacrimation and conjunctivitis.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Very common: headache, palpitations, tachycardia. Common: dizziness, angina symptoms, hypotension, flushing, nasal congestion, gastrointestinal disturbances (diarrhoea, nausea, vomiting), arthralgia, myalgia, joint swelling and SLE-like syndrome (sometimes fatal). Rare: blood dyscrasias, hypersensitivity reactions including vasculitis, hepatitis/jaundice, heart failure, proteinuria/haematuria with glomerulonephritis. Many effects occur at the start of therapy, especially with rapid dose increases, and generally subside.International label, equivalent formulation · electronic medicines compendium (eMC)

• Hypersensitivity to hydralazine; coronary artery disease; mitral valvular rheumatic heart disease.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to hydralazine, dihydralazine or excipients; idiopathic systemic lupus erythematosus and related diseases; severe tachycardia; high-output cardiac failure (e.g. thyrotoxicosis); myocardial insufficiency due to mechanical obstruction (e.g. mitral or aortic stenosis, constrictive pericarditis); cor pulmonale; dissecting aortic aneurysm; porphyria.International label, equivalent formulation · electronic medicines compendium (eMC)

• Hydralazine may produce a syndrome resembling systemic lupus erythematosus, including glomerulonephritis; discontinue unless the benefit-risk requires continued therapy; symptoms usually regress on withdrawal but residua have been detected many years later; long-term steroid treatment may be necessary.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Myocardial stimulation can cause anginal attacks and ECG changes of ischaemia and has been implicated in myocardial infarction - use with caution in suspected coronary artery disease; may increase pulmonary artery pressure in mitral valvular disease; postural hypotension may occur; use with caution in cerebrovascular accidents and advanced renal damage.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Peripheral neuritis (paraesthesia, numbness, tingling) has been observed, suggesting an antipyridoxine effect - add pyridoxine if symptoms develop; blood dyscrasias (reduced haemoglobin and red cells, leukopenia, agranulocytosis, purpura) have been reported - withdraw if abnormalities develop.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Monoamine oxidase inhibitors (MAOIs)MAO inhibitors should be used with caution in patients receiving hydralazine.DailyMed (U.S. National Library of Medicine)
• Diazoxide and other potent parenteral antihypertensivesObserve patients continuously for several hours for an excessive fall in blood pressure; profound hypotensive episodes may occur when diazoxide injection and hydralazine are used together.DailyMed (U.S. National Library of Medicine)
• Other antihypertensives, anaesthetics, tricyclic antidepressants, major tranquillisers, nitrates and CNS depressants including alcoholThese enhance the hypotensive effect of hydralazine; giving hydralazine within an hour or two of diazoxide may cause marked hypotension.electronic medicines compendium (eMC)

• There are no adequate and well-controlled studies in pregnant women; hydralazine should be used during pregnancy only if the expected benefit justifies the potential risk to the fetus.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Women planning to become pregnant should not take hydralazine; if pregnancy is confirmed during treatment, stop it immediately (the SmPC allows later-pregnancy use only when mother or fetus is at risk).International label, equivalent formulation · electronic medicines compendium (eMC)
• Hydralazine has been shown to be excreted in breast milk.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Hydralazine: Precise mechanism not fully understood; lowers blood pressure by a peripheral vasodilating effect through direct relaxation of vascular (mainly arteriolar) smooth muscle, reducing peripheral resistance with reflex increases in heart rate, stroke volume and cardiac output (US label).